Ariad’s Iclusig Has A Strong Launch Trajectory After First Three Months
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech gave investors a surprise update about the status of its recently-launched leukemia drug after a sell-side analyst had investors questioning whether the drug was selling as expected.